Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Public ClinicalTrials.gov record NCT00630032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.
Study identification
- NCT ID
- NCT00630032
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UNICANCER
- Other
- Enrollment
- 762 participants
Conditions and interventions
Conditions
Interventions
- cyclophosphamide Drug
- Docetaxel Drug
- epirubicin hydrochloride Drug
- fluorouracil Drug
- ixabepilone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- May 31, 2017
- Completion
- Sep 2, 2020
- Last update posted
- Feb 20, 2024
2007 – 2020
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Scottsdale | Scottsdale | Arizona | 85259-5499 | — |
| CCOP - Colorado Cancer Research Program | Denver | Colorado | 80224 | — |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| CCOP - Northern Indiana CR Consortium | South Bend | Indiana | 46601 | — |
| CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa | 52403-1206 | — |
| Siouxland Hematology-Oncology Associates, LLP | Sioux City | Iowa | 51101-1733 | — |
| Cancer Center of Kansas, PA - Wichita | Wichita | Kansas | 67214-3728 | — |
| Duluth Clinic Cancer Center - Duluth | Duluth | Minnesota | 55805-1983 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| CCOP - Metro-Minnesota | Saint Louis Park | Minnesota | 55416 | — |
| Southeast Nebraska Hematology Oncology Consultants at Southeast Nebraska Cancer Center | Lincoln | Nebraska | 68510 | — |
| CCOP - Missouri Valley Cancer Consortium | Omaha | Nebraska | 68106 | — |
| Roger Maris Cancer Center at MeritCare Hospital | Fargo | North Dakota | 58122 | — |
| CCOP - Dayton | Dayton | Ohio | 45429 | — |
| CCOP - Geisinger Clinic and Medical Center | Danville | Pennsylvania | 17822-2001 | — |
| Oncology Associates at Rapid City Regional Hospital | Rapid City | South Dakota | 57701 | — |
| Green Bay Oncology, Limited at St. Mary's Hospital | Green Bay | Wisconsin | 54303 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00630032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2024 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00630032 live on ClinicalTrials.gov.